加载中
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
前收盘价
US$4.22
+US$0.04 · +0.96%
盘前
US$4.22
US$0.00 · 0.00%
10月12日 4:00 ET
盘中时间采用ET。市场数据可能有所延迟。
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
日内区间
当前US$4.22
52周区间
当前US$4.22
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
87
深度低估
情绪
54
多空交织
风险
33
中等风险
动量
59
中性
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
日内区间
当前US$4.22
52周区间
当前US$4.22
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1408.3万 USD | 617.1万 USD | 1814.1万 USD | 3901.9万 USD | 1098.8万 USD |
| 销货成本 | 36.3万 USD | — | — | — | — |
| 毛利 | 1372万 USD | 617.1万 USD | 1814.1万 USD | 3901.9万 USD | 1098.8万 USD |
| 研究与开发 | 2524.1万 USD | 5403.7万 USD | 7370万 USD | 8440.8万 USD | 6550.2万 USD |
| 销售、一般及管理费用 | 1589.3万 USD | 2210.8万 USD | 2247.5万 USD | 1783.4万 USD | 1713.6万 USD |
| 营业费用 | 4077.1万 USD | 8249万 USD | 9624.4万 USD | 1.04亿 USD | 8451万 USD |
| 利息收入 | 406.8万 USD | 658.5万 USD | 568.8万 USD | 219.2万 USD | 12.7万 USD |
| 利息支出 | 9.7万 USD | 13.7万 USD | 45.9万 USD | 172.6万 USD | 285.7万 USD |
| 折旧和摊销 | 36.3万 USD | 138万 USD | 140.4万 USD | 142.7万 USD | 175.3万 USD |
| 营业利润 | −2705.1万 USD | −7631.9万 USD | −7810.3万 USD | −6545.6万 USD | −7352.2万 USD |
| 净利润 | −3350.1万 USD | −6992万 USD | −7284.9万 USD | −6945.6万 USD | −7624.7万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2010年11月4日 | 1:5 | — | — |
已生效 2010年11月4日
1:5
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2557.55万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM1734.22万0.02%787.4亿 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI1183.19万0.12%98.74亿 USD0.35%US$153.77+3.00%
Vanguard Extended Market ETFVXF931.49万0.01%954亿 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO627.47万0.05%139.17亿 USD0.24%US$356.78+0.94%
iShares Biotechnology ETFIBB516.86万0.05%108.2亿 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO469.08万0.03%180亿 USD0.06%US$112.66+0.50%
Janus Henderson Small Cap Growth Alpha ETFJSML382.89万1.06%3.61亿 USD0.30%US$87.477+1.00%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOJanus Henderson Small Cap Growth Alpha ETFJSMLAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
